Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
Researchers are studying how personalized coaching based on patient typology affects therapy persistence in patients with HRHER2- early breast cancer who are taking ribociclib. The study aims to compare the time it takes for patients to permanently stop treatment between those receiving personalized coaching and those who receive only standard care education and counseling. This research focuses on improving adherence to ribociclib therapy. Participants are randomly assigned to one of two groups one group receives personalized therapy coaching tailored to their patient typology using the MASCC Oral Agent Teaching Tool MOATT, and the other group receives standard care patient counseling without additional coaching. The study evaluates behavioral interventions related to therapy management over a period that could extend up to five years. During the study, participants will have scheduled visits and follow the treatment plans and trial procedures as required. Researchers will monitor the time to permanent discontinuation of ribociclib treatment as the primary outcome, with secondary measures including ribociclib persistence rates at 6, 12, and 36 months after therapy begins. Participants are expected to comply with visits and assessments throughout the study duration, which may last up to five years.
Actively Recruiting
Researchers are conducting a multi-center, prospective, non-interventional study in Germany to collect real-world clinical and patient-reported data from women with primary advanced FIGO stage III or IV or recurrent endometrial cancer receiving first-line treatment. The study evaluates two maintenance therapies following chemotherapy with Carboplatin, Paclitaxel, and Durvalumab CPD, focusing on outcomes in patients with different tumor DNA mismatch repair statuses. The goal is to understand the effectiveness, safety, and patient experiences with these treatments in routine clinical practice. Participants receive first-line CPD chemotherapy. Those with DNA mismatch repair deficient tumors dMMR cohort receive maintenance therapy with durvalumab alone if their disease is controlled after chemotherapy. Participants with DNA mismatch repair proficient tumors pMMR cohort receive maintenance therapy with durvalumab and olaparib under similar conditions. Treatment decisions are based on standard care guidelines and made jointly by patients and their physicians. The study follows patients over time to observe treatment duration and transitions. During the study, participants complete patient-reported outcome questionnaires to assess quality of life and symptom changes after chemotherapy. Clinical data including time to next treatment and progression-free survival are collected up to 46 months. The study also tracks maintenance therapy duration, chemotherapy duration, and timing between chemotherapy and maintenance start. Safety and treatment use are monitored as part of routine care. Overall, the study provides long-term real-world insights into first-line and maintenance therapy for endometrial cancer.
Actively Recruiting
Researchers are gathering real-world data from patients in Germany with non-squamous metastatic non-small cell lung cancer NSQ mNSCLC, including large cell neuroendocrine carcinoma when considered similar to NSCLC. The study focuses on patients beginning their first-line treatment with a combination of tremelimumab, durvalumab, and platinum-based chemotherapy TDC as approved. It aims to understand treatment effectiveness based on specific genetic mutations like KRAS, STK11, KEAP1, TP53, and markers such as TTF-1 and PD-L1 to help guide personalized treatment strategies for high-need patient subgroups. Participants are observed without receiving additional interventions beyond their planned standard treatment with TDC. The study collects data according to routine clinical practice during the patients treatment course. Biomarker testing including molecular sequencing and expression analyses is performed as per institutional standards to classify patient subgroups. During the study, participants survival and treatment responses are tracked for up to 24 months, with key outcomes including real-world overall survival rates at two years, progression-free survival, and safety through adverse event collection. Data are gathered at multiple time points up to two years to evaluate outcomes in the overall population and in subgroups defined by genetic mutations. Participants provide informed consent and must meet specific eligibility criteria to join.
Actively Recruiting
Researchers are studying patients with breast cancer, focusing on those with metastatic disease who typically have the poorest outlook. The trial aims to improve treatment decisions and quality of care by analyzing tumor characteristics. Although national guidelines recommend molecular reassessment of metastatic tumors, biopsies are rare due to invasiveness, so the study explores blood-based methods to assess tumor features and their relation to treatment outcomes and health economics. The study involves two groups about 3,500 patients with locally advanced or metastatic breast cancer receiving any line of treatment, and approximately 10,000 patients with early breast cancer undergoing neoadjuvant or adjuvant therapy regardless of regimen. Blood samples will be collected during routine blood draws to analyze tumor molecular characteristics and biomarkers for progression and survival. Participants will be followed with assessments including quality of life, therapy adherence, depression factors, and adverse events at study entry and regularly up to 60 months. The study will measure progression-free survival in metastatic breast cancer and disease-free survival in early breast cancer, along with overall survival and health economic outcomes. Results of molecular testing will be shared with patients at study end, providing comprehensive data to support improved breast cancer care.
Actively Recruiting
This clinical trial investigates whether Resilience PRO, a digital tool for remote symptom monitoring, can improve the quality of life for adults diagnosed with cancer who are receiving systemic anticancer treatment. The study compares patients using Resilience PRO plus their usual care to those receiving usual care alone. Resilience PRO is approved by French health authorities and designed to collect patient-reported outcomes electronically. Participants in the intervention group will use the Resilience PRO mobile app, which regularly asks about symptoms and sends alerts to the care team when important symptoms are reported. This allows timely adjustment of care. Both the intervention and control groups will continue to receive their usual cancer treatment and care. The trial is randomized and open-label. Throughout the study, researchers will measure quality of life after 3 months as the primary outcome. They will also evaluate health economics over 12 months and overall survival over 36 months. Participants will be monitored remotely using the app, and the study will assess how symptom monitoring affects their care and well-being over time.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.